Century Therapeutics: A Very Promising Contender In The Type I Diabetes Mellitus Functional Cure Race

Century Therapeutics (IPSC) aims at a durable “once-and-done” Type 1 diabetes cure with hypoimmune iPSC beta cells; runway to 2029—click here to read now.

The Income Method: How To Use Cash Flow To Fund Your Retirement

Good investors know patience is a virtue. Read more about building a diversified, resilient retirement income portfolio with ...

Affinia Therapeutics Announces FDA Acceptance of IND Application to Advance AFTX-201 to a Phase 1/2 Trial for the Treatment of BAG3-Associated Dilated Cardiomyopathy (DCM)

The UPBEAT (c) clinical trial is a multicenter, open-label Phase 1/2 clinical trial designed to evaluate the safety, tolerability, pharmacodynamics, and preliminary efficacy of AFTX-201 in adults with ...